Stay updated on Pembrolizumab in Recurrent PCNSL Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Recurrent PCNSL Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    No significant content changes are evident; the updates appear to be minor UI/visual adjustments without altering the study details such as eligibility, endpoints, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-10-27T20:53:28.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    Update includes a prominent operating-status notice and a version upgrade from v3.1.0 to v3.2.0. The core effect is informing users about possible delays and the current open status of the NIH Clinical Center.
    Difference
    4%
    Check dated 2025-10-06T07:58:45.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The page shows a version upgrade from v3.0.2 to v3.1.0 and adds a new extension/contact code (+43140400 ext 44450).
    Difference
    0.1%
    Check dated 2025-09-29T04:35:48.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Output version updated from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed; no changes to core content, pricing, stock, or time slots.
    Difference
    0.2%
    Check dated 2025-09-14T21:55:57.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-07T19:08:42.000Z thumbnail image
  8. Check
    60 days ago
    Change Detected
    Summary
    The web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new medical terms related to primary central nervous system lymphoma and pembrolizumab. However, many related topics and previous versions have been removed.
    Difference
    3%
    Check dated 2025-08-31T12:22:28.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Recurrent PCNSL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Recurrent PCNSL Clinical Trial page.